Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.

ABSTRACT:

Clinical trials registration

NCT02263326.

SUBMITTER: Taiwo BO 

PROVIDER: S-EPMC5961309 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature